Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 7, 2013, Pages 504-508

  Bostrom, Bruce ^a   Uppal, Priya ^a   Chu, Julie ^a   Messinger, Yoav ^a   Gandrud, Laura ^a   McEvoy, Robert ^a  

^a CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

Author keywords

corticosteroids; hyperglycemia; leukemia; metformin; pegasparaginase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARAGINASE MACROGOL; BILIRUBIN; CORTICOSTEROID; CREATININE; DEXAMETHASONE; GLUCOSE; INSULIN; MEGESTROL; METFORMIN; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84885189547     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31829cdeba     Document Type: Article

References (25)

1. Howard SC, Pui CJ. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002;16:225-243.
2. Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr. 1978;93:775-778.
3. Gailani S, Nussbaum A, Onuma T, et al. Diabetes in patients treated with asparaginase. Clin Pharmacol Ther. 1971;12:487-490.
4. Pui CH, Burghen GA, Bowman WP, et al. Risk factors for hyperglycemia in children with leukemia receiving SC L-asparaginase and prednisone. J Pediatr. 1981;99:46-50.
5. Koltin D, Sung L, Naqvi A, et al. Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Cancer. 2012;20:2009-2015.
6. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 52:814-818.
7. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, et al. Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol. 2009;7:465-472.
8. Sonabend RY, Siripoom VM, Okcu F, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr. 2009; 155:73-78.
9. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012;35:119-124.
10. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathological complete response to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27: 3297-3302.
11. Shi WY, Xiao D, Wang L, et al. Therapeutic metformin/ AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012;3:e275.
12. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009;145:569-580.
13. Ashour AE, Sayed-Ahmed MM, Abd-Allah AR, et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxid Med Cell Longev. 2012;2012:434195.
14. Asensio-Ló pez MC, Sánchez-Má s J, Pascual-Figal DA, et al. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. Free Radic Biol Med. 2012;57:188-200.
15. Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol. 2006;4:479-483.
16. Aisner J, Tchekmedyian NS, Moody M, et al. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities. Semin Hematol. 1987;24(suppl 1):48-55.
17. Common Terminology Criteria for Adverse Events (CTCAE) v3. 0. Available at: http://ctep. cancer. gov/protocolDevelopment/ electronic-applications/docs/ ctcaev3. pdf.
18. Segal I, Rassekh SR, Bond MC, et al. Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;55:434-439.
19. Farrow AC, Buchanan GR, Zwiener RJ, et al. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15:1560-1566.
20. Roberson JR, Raju S, Shelso J, et al. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:1207-1212.
21. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33: 727-740.
22. Aguilar C, Reza A, Garcia JE, et al. Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res. 1992;23: 19-24.
23. Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother. 2004;38:776-780.
24. Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc. 2010;50:407-410.
25. Alvarez JA, Scully RE, Miller TL, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr. 2007; 19:23-31.